The Medicines and Medical Devices Bill seeks to address this regulatory gap through introducing regulation-making, delegated powers covering the fields of human medicines, clinical trials of human medicines, veterinary medicines and medical devices. Its purpose is to enable the existing regulatory frameworks to be updated at the end of the Transition Period.
“The Bill is necessitated by Brexit but as many noble lords have said it does not provide detail required to address the concerns about protecting patient’s safety, promoting innovation and helping British businesses at such a difficult time.” Lord Rennard calls for a close alignment for regulation between the UK the EU and other international standard bodies. There is a concern that patients in the UK will be accessing the latest innovations significantly later than patients in the EU.
See archived appearances in parliament.